4147.TWO - TaiMed Biologics Inc.

Taipei Exchange - Taipei Exchange Delayed Price. Currency in TWD

TaiMed Biologics Inc.

No. 607, Ruiguang Road
3rd Floor Neihu District
Taipei City 11492
886 2 2658 0058

Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
James Chang Ph.D.CEO, Pres & DirectorN/AN/AN/A
Dr. David D. HoScientific Co-Founder, Chief Scientific Advisor and Board DirectorN/AN/AN/A
Dr. Ing-Wen Tsai Ph.D.Co-FounderN/AN/AN/A
Dr. Lan-Bo Chen Ph.D.Co-FounderN/AN/AN/A
Jack ChenChief Financial OfficerN/AN/AN/A
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in TWD.


TaiMed Biologics Inc., a biotechnology company, develops health-care products. The company develops and markets TMB-355, a humanized monoclonal antibody intravenous infusion for the treatment of HIV-1 infection. It is also developing TMB-355, a humanized monoclonal antibody intramuscular injection, which is in Phase II clinical trial for treating HIV/AIDS; TMB-607, a novel HIV-1 protease inhibitor that is in Phase I clinical trial; TMB-365, an anti-CD4 recombinant humanized monoclonal antibody, which is in Phase I clinical trial for treating HIV infections; TMB-Bispecific, a bispecific neutralizing antibody that is in Phase I clinical trial to treat HIV infections; and TMB-ADC, an antibody–drug conjugate for treating HIV infection. The company was founded in 2007 and is based in Taipei City, Taiwan.

Corporate Governance

TaiMed Biologics Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.